IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery ...
Intermediate-risk patients who received transcatheter aortic valve replacement, known as TAVR, with the latest-generation valve fared better than patients receiving traditional surgical aortic valve ...
FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
First-of-a-kind health economics study found lifetime per-patient savings from early TAVR range from £1,788 in the UK to CHF ...
Please provide your email address to receive an email when new articles are posted on . Researchers analyzed outcomes among only women who underwent TAVR or surgery. TAVR was superior to surgery for ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio BOSTON — Transcatheter aortic valve ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
TCT: Medtronic, Edwards' longer-term TAVR studies continue to perform on par with open-heart surgery
Ongoing long-term studies from the two major producers of transcatheter aortic valve replacements showed the minimally invasive route can continue to perform on par with open-heart surgery in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback